Dynavax (DVAX) Receives a Buy from Cantor Fitzgerald


In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Dynavax (DVAX), with a price target of $28. The company’s shares opened today at $10.56.

Piros commented:

“. We are reiterating our Overweight rating and lowering our 12-month price target to $28/share from $32/share, following financial and corporate updates from 4Q18/2018. Dynavax reported 4Q18 HEPLISAV-B sales of $3.9 million (a beat on our $3.4 million estimate) from $1.5 million in sales during 3Q18. We are encouraged by the first launch year and expect updates from the SD-101 program (data and partnership talks) to be a key focus for investors during 2019.”

According to TipRanks.com, Piros has 0 stars on 0-5 star ranking scale with an average return of -3.5% and a 42.7% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.

Dynavax has an analyst consensus of Hold.

See today’s analyst top recommended stocks >>

The company has a one-year high of $22.80 and a one-year low of $7.85. Currently, Dynavax has an average volume of 998.1K.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts